Keytruda And Small Cell Lung Cancer

Keytruda is a prescription medicine used to treat a kind of lung cancer called non small cell lung cancer nsclc.

Keytruda and small cell lung cancer.

Keytruda pembrolizumab is used to treat advanced melanoma non small cell lung cancer small cell lung cancer head and neck squamous cell carcinoma classical hodgkin lymphoma primary mediastinal large b cell lymphoma urothelial carcinoma microsatellite instability high cancer gastric cancer esophageal cancer cervical cancer hepatocellular carcinoma merkel cell carcinoma renal cell. Merck co s keytruda may be the star in non small cell lung cancer but a combo of it and chemo just failed to significantly outdo chemo alone at prolonging patients lives in small cell. On june 17 2019 the food and drug administration granted accelerated approval to pembrolizumab keytruda merck for patients with metastatic small cell lung cancer sclc with disease. The immunotherapy agent keytruda pembrolizumab had an overall response rate orr of 33 percent in a recent trial including patients with extensive stage small cell lung cancer sclc.

Keytruda may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread advanced nsclc and is a type called nonsquamous and your tumor does not have an abnormal egfr or alk gene.